Evidence mapPaperPMID 42465030Full record

ArticleAmerican journal of cancer research2026

RPS2 and EEF1B2 are associated with glycolysis-related malignant phenotypes in COAD.

Jianbin Hou, Yangyang Dong, Huiyang Qian

Abstract read
In one paragraph

Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jianbin HouQuanzhou First Hospital Affiliated to Fujian Medical University Quanzhou 362000, Fujian, China.
Yangyang DongQuanzhou First Hospital Affiliated to Fujian Medical University Quanzhou 362000, Fujian, China.
Huiyang QianQuanzhou First Hospital Affiliated to Fujian Medical University Quanzhou 362000, Fujian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lactate metabolism-related reprogramming is closely associated with colon adenocarcinoma (COAD) progression, but related key molecules remain unclear. This study integrated the colorectal cancer single-cell RNA sequencing dataset GSE231559, which served as a single-cell reference and integrated it with bulk RNA-seq data from TCGA-COAD to screen lactate metabolism-related candidate genes. Epithelial cells showed higher lactate metabolism-related transcriptional scores. An overlap-based screening strategy was applied, encompassing three gene sets: epithelial markers associated with lactate metabolism, dysregulated transcripts in the TCGA colon adenocarcinoma cohort, and genes within the co-expression module correlated with the lactate score. This analysis prioritized 14 genes for subsequent investigation. RPS2 and EEF1B2 were selected for further validation. Public database analysis and immunohistochemistry of paired tissues from 50 patients with COAD showed that RPS2 and EEF1B2 were highly expressed in tumor tissues. In HT-29 cells, siRNA-mediated knockdown of RPS2 or EEF1B2 reduced proliferation and migration, increased apoptosis, and decreased HK2, PFK1, PKM2, and LDHA expression, with stronger changes after double knockdown. RPS2 knockdown also increased residual glucose levels and reduced lactate release. Co-immunoprecipitation showed that RPS2 and EEF1B2 were detected in the same protein complex, and EEF1B2 overexpression partially rescued the effects of RPS2 knockdown. These findings suggest that RPS2 and EEF1B2 are associated with glycolysis-related malignant phenotypes in HT-29 cells.

Indexed as

Colon adenocarcinomaEEF1B2glycolysislactate metabolismRPS2single-cell RNA sequencing

Identifiers

PMID42465030
PMCPMC13373562

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.